USE OF MR IMAGING CONTRAST AGENTS IN THE BRAIN

被引：19

作者：

BRADLEY, WG

YUH, WTC

BYDDER, GM

机构：

[1] Memorial MR Center, Long Beach Memorial Medical Center, Long Beach, California, 90806

[2] Department of Radiology, The University of Iowa College of Medicine, Iowa City, Iowa

[3] Hammersmith Hospital, Royal Postgraduate Medical School, London

来源：

JMRI-JOURNAL OF MAGNETIC RESONANCE IMAGING | 1993年 / 3卷 / 01期

关键词：

BRAIN; DISEASES; INFARCTION; INFECTION; MR; BRAIN NEOPLASMS; CONTRAST ENHANCEMENT; GADOLINIUM; PITUITARY; NEOPLASMS;

D O I：

10.1002/jmri.1880030133

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

AS A RULE, ANYTHING that enhances with iodine on computed tomographic (CT) scans of the brain enhances on magnetic resonance (MR) images with gadopentetate dimeglumine (Magnevist; Berlex Laboratories, Wayne, NJ) (1). This is because ionic iodinated agents (eg, diatrizoate meglumine [Renografin; Squibb, New Brunswick, NJ]) have a charge and size similar to those of gadopentetate dimeglumine. Thus, lesions producing similar degrees of blood-brain barrier breakdown allow passage of either gadolinium or iodinated contrast medium from the intravascular to the extracellular space with subsequent increased signal intensity, or enhancement. Obviously, such lesions must also be perfused (ie, the blood supply to the lesion must be intact) as a prerequisite for enhancement with either agent (1). While almost all lesions that enhance visibly with iodinated agents will also enhance with gadopentetate dimeglumine, the converse is not true. As is true for a comparison of unenhanced MR imaging with unenhanced CT in general, posterior fossa enhancement is better appreciated with MR imaging than with CT because of beam-hardening artifacts in the latter (2).

引用

页码：199 / 218

页数：20

共 36 条

[1] Bydder GM, Clinical application of gadolinium‐DTPA, Magnetic resonance imaging, pp. 182-200, (1988)
[2] Bradley WG, Waluch V, Yadley RA, Wycoff RR, Comparison of CT and MR in 400 patients with suspected disease of the brain and cervical spinal cord, Radiology, 152, pp. 695-702, (1984)
[3] Palmer FJ, The RACR survey of intravenous contrast media reaction: final report, Aust Radiol, 32, pp. 426-428, (1988)
[4] Caro JJ, Trindade E, McGregor M, Risks of death and of severe nonfatal reactions with high‐vs low‐osmolality contrast media: a meta‐analysis, AJR, 156, pp. 825-832, (1991)
[5] Yuh WTC, Fisher DJ, Engleken JD, Et al., MR evaluation of CNS tumors: Dose comparison study with gadopentetate dimeglumine and gadoteridol, Radiology, 180, pp. 485-491, (1991)
[6] Runge VM, Gelblum DY, Pacetti ML, Carolan F, Heard G, Gd‐HP‐DO3A in clinical MR imaging of the brain, Radiology, 177, pp. 393-400, (1990)
[7] Niendorf HP, Laniado M, Semmler W, Schorner W, Felix R, Dose administration of gadolinium‐DTPA in MR imaging of intracranial tumors, AJNR, 8, pp. 803-815, (1987)
[8] Graif M, Bydder GM, Steiner RE, Niendorf P, Thomas DGT, Young IR, Contrast‐enhanced MR imaging of malignant brain tumors, AJNR, 6, pp. 855-862, (1985)
[9] Schorner W, Laniado M, Niendorf HP, Schubert C, Felix R, Time‐dependent changes in image contrast in brain tumors after gadolinium‐DTPA, AJNR, 7, pp. 1013-1020, (1986)
[10] Bydder GM, Kingsley PE, Brown J, Niendorf HP, Young IR, MR imaging of meningiomas including studies with and without gadolinium‐DTPA, J Comput Assist Tomogr, 9, pp. 690-697, (1985)

← 1 2 3 4 →